Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

NCT03768570 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

82

Enrollment

NETWORK

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: Durvalumab

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]